LeMaitre Research Development vs Ebitda Analysis

LMAT Stock

USD 107.97 2.10 1.98%

LeMaitre Vascular financial indicator trend analysis is infinitely more than just investigating LeMaitre Vascular recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether LeMaitre Vascular is a good investment. Please check the relationship between LeMaitre Vascular Research Development and its Ebitda accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LeMaitre Vascular. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy LeMaitre Stock please use our How to Invest in LeMaitre Vascular guide.

Research Development vs Ebitda

Research Development vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of LeMaitre Vascular Research Development account and Ebitda. At this time, the significance of the direction appears to have almost identical trend.

The correlation between LeMaitre Vascular's Research Development and Ebitda is 0.94. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Ebitda in the same time period over historical financial statements of LeMaitre Vascular, assuming nothing else is changed. The correlation between historical values of LeMaitre Vascular's Research Development and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of LeMaitre Vascular are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Research Development i.e., LeMaitre Vascular's Research Development and Ebitda go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Ebitda

Most indicators from LeMaitre Vascular's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into LeMaitre Vascular current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LeMaitre Vascular. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy LeMaitre Stock please use our How to Invest in LeMaitre Vascular guide.At this time, LeMaitre Vascular's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 26.92 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 6.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	101.4M	104.9M	127.0M	133.4M
Total Revenue	154.4M	161.7M	193.5M	203.2M

Gross Profit Total Revenue

LeMaitre Vascular fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Other Assets	Long Term Debt	Net Receivables	Good Will
Total Assets		0.3	0.53	0.97	0.99	0.5	0.97	0.21	0.67	0.82	0.97	0.84	0.97	0.53	0.27	0.92	0.65	0.44	0.98	0.32	0.99	0.96	0.34	0.9	0.83	0.98
Short Long Term Debt Total	0.3		-0.03	0.39	0.2	0.57	0.44	-0.32	0.46	-0.06	0.17	0.7	0.14	0.86	0.55	-0.01	0.82	0.48	0.31	0.56	0.23	0.23	0.94	0.31	0.47	0.42
Other Current Liab	0.53	-0.03		0.59	0.57	-0.28	0.37	0.14	0.4	0.63	0.6	0.25	0.67	0.27	0.52	0.73	0.02	0.03	0.43	-0.45	0.52	0.61	-0.07	0.37	0.38	0.39
Total Current Liabilities	0.97	0.39	0.59		0.95	0.46	0.94	0.1	0.73	0.73	0.92	0.87	0.94	0.56	0.38	0.87	0.68	0.52	0.96	0.32	0.96	0.97	0.4	0.92	0.85	0.95
Total Stockholder Equity	0.99	0.2	0.57	0.95		0.41	0.95	0.2	0.67	0.84	0.99	0.77	0.99	0.48	0.26	0.95	0.55	0.39	0.96	0.24	0.98	0.96	0.24	0.87	0.82	0.96
Net Debt	0.5	0.57	-0.28	0.46	0.41		0.66	0.34	0.1	0.33	0.3	0.79	0.31	0.43	-0.24	0.18	0.88	0.37	0.6	0.77	0.51	0.44	0.73	0.57	0.39	0.63
Non Current Assets Total	0.97	0.44	0.37	0.94	0.95	0.66		0.18	0.65	0.74	0.91	0.92	0.9	0.61	0.23	0.81	0.78	0.5	0.97	0.5	0.96	0.91	0.5	0.9	0.83	1.0
Non Currrent Assets Other	0.21	-0.32	0.14	0.1	0.2	0.34	0.18		-0.51	0.63	0.11	0.13	0.23	-0.24	-0.49	0.27	0.11	-0.22	0.24	-0.11	0.29	0.24	-0.02	0.22	-0.13	0.18
Common Stock Shares Outstanding	0.67	0.46	0.4	0.73	0.67	0.1	0.65	-0.51		0.25	0.71	0.57	0.65	0.65	0.67	0.59	0.42	0.64	0.62	0.27	0.62	0.63	0.27	0.58	0.9	0.66
Other Current Assets	0.82	-0.06	0.63	0.73	0.84	0.33	0.74	0.63	0.25		0.8	0.56	0.86	0.24	0.03	0.88	0.37	0.13	0.78	0.03	0.85	0.81	0.1	0.69	0.51	0.75
Other Stockholder Equity	0.97	0.17	0.6	0.92	0.99	0.3	0.91	0.11	0.71	0.8		0.7	0.98	0.48	0.31	0.96	0.47	0.33	0.91	0.17	0.94	0.93	0.17	0.81	0.81	0.92
Total Liab	0.84	0.7	0.25	0.87	0.77	0.79	0.92	0.13	0.57	0.56	0.7		0.71	0.7	0.3	0.58	0.95	0.6	0.88	0.61	0.82	0.8	0.77	0.84	0.75	0.9
Total Current Assets	0.97	0.14	0.67	0.94	0.99	0.31	0.9	0.23	0.65	0.86	0.98	0.71		0.43	0.29	0.98	0.48	0.35	0.93	0.13	0.97	0.97	0.17	0.85	0.79	0.91
Short Term Debt	0.53	0.86	0.27	0.56	0.48	0.43	0.61	-0.24	0.65	0.24	0.48	0.7	0.43		0.67	0.33	0.71	0.34	0.47	0.35	0.45	0.43	0.77	0.41	0.71	0.6
Cash	0.27	0.55	0.52	0.38	0.26	-0.24	0.23	-0.49	0.67	0.03	0.31	0.3	0.29	0.67		0.26	0.23	0.36	0.16	-0.12	0.2	0.26	0.36	0.17	0.47	0.24
Cash And Short Term Investments	0.92	-0.01	0.73	0.87	0.95	0.18	0.81	0.27	0.59	0.88	0.96	0.58	0.98	0.33	0.26		0.32	0.23	0.86	-0.03	0.92	0.92	0.02	0.77	0.72	0.83
Non Current Liabilities Total	0.65	0.82	0.02	0.68	0.55	0.88	0.78	0.11	0.42	0.37	0.47	0.95	0.48	0.71	0.23	0.32		0.57	0.71	0.71	0.62	0.59	0.9	0.67	0.59	0.76
Other Liab	0.44	0.48	0.03	0.52	0.39	0.37	0.5	-0.22	0.64	0.13	0.33	0.6	0.35	0.34	0.36	0.23	0.57		0.51	0.58	0.46	0.44	0.45	0.52	0.62	0.5
Property Plant And Equipment Net	0.98	0.31	0.43	0.96	0.96	0.6	0.97	0.24	0.62	0.78	0.91	0.88	0.93	0.47	0.16	0.86	0.71	0.51		0.43	0.98	0.97	0.38	0.93	0.81	0.97
Current Deferred Revenue	0.32	0.56	-0.45	0.32	0.24	0.77	0.5	-0.11	0.27	0.03	0.17	0.61	0.13	0.35	-0.12	-0.03	0.71	0.58	0.43		0.31	0.23	0.59	0.46	0.36	0.47
Retained Earnings	0.99	0.23	0.52	0.96	0.98	0.51	0.96	0.29	0.62	0.85	0.94	0.82	0.97	0.45	0.2	0.92	0.62	0.46	0.98	0.31		0.96	0.31	0.92	0.81	0.97
Accounts Payable	0.96	0.23	0.61	0.97	0.96	0.44	0.91	0.24	0.63	0.81	0.93	0.8	0.97	0.43	0.26	0.92	0.59	0.44	0.97	0.23	0.96		0.27	0.88	0.78	0.92
Other Assets	0.34	0.94	-0.07	0.4	0.24	0.73	0.5	-0.02	0.27	0.1	0.17	0.77	0.17	0.77	0.36	0.02	0.9	0.45	0.38	0.59	0.31	0.27		0.37	0.4	0.48
Long Term Debt	0.9	0.31	0.37	0.92	0.87	0.57	0.9	0.22	0.58	0.69	0.81	0.84	0.85	0.41	0.17	0.77	0.67	0.52	0.93	0.46	0.92	0.88	0.37		0.76	0.9
Net Receivables	0.83	0.47	0.38	0.85	0.82	0.39	0.83	-0.13	0.9	0.51	0.81	0.75	0.79	0.71	0.47	0.72	0.59	0.62	0.81	0.36	0.81	0.78	0.4	0.76		0.84
Good Will	0.98	0.42	0.39	0.95	0.96	0.63	1.0	0.18	0.66	0.75	0.92	0.9	0.91	0.6	0.24	0.83	0.76	0.5	0.97	0.47	0.97	0.92	0.48	0.9	0.84

Click cells to compare fundamentals

LeMaitre Vascular Account Relationship Matchups

LeMaitre Vascular fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	188.3M	252.8M	292.8M	310.5M	346.8M	364.1M
Other Current Liab	2.5M	5.3M	4.9M	7.4M	20.8M	21.9M
Total Current Liabilities	20.9M	25.1M	21.8M	25.3M	29.9M	31.4M
Total Stockholder Equity	148.1M	172.6M	254.2M	268.2M	297.9M	312.8M
Net Debt	3.9M	28.0M	2.1M	(2.5M)	(5.2M)	(5.4M)
Non Current Assets Total	96.2M	158.5M	152.9M	148.7M	152.2M	159.8M
Non Currrent Assets Other	259K	909K	568K	991K	3.7M	3.9M
Common Stock Shares Outstanding	20.3M	20.5M	21.5M	22.2M	22.4M	17.3M
Liabilities And Stockholders Equity	188.3M	252.8M	292.8M	310.5M	346.8M	364.1M
Other Current Assets	3.3M	5.2M	8.4M	6.7M	12.1M	12.7M
Other Stockholder Equity	94.9M	103.3M	169.2M	176.2M	186.9M	196.2M
Total Liab	40.2M	80.2M	38.7M	42.3M	48.9M	51.3M
Total Current Assets	92.1M	94.3M	139.9M	161.7M	194.6M	204.3M
Short Term Debt	1.8M	6.4M	3.7M	3.8M	4.9M	2.5M
Cash	11.8M	26.8M	13.9M	19.1M	24.3M	18.3M
Cash And Short Term Investments	32.7M	27.0M	70.0M	82.7M	105.1M	110.3M
Non Current Liabilities Total	19.3M	55.1M	16.8M	16.9M	19.0M	19.9M
Other Liab	5.4M	4.8M	2.8M	2.2M	2.6M	1.8M
Property Plant And Equipment Net	30.1M	31.1M	32.1M	33.5M	39.8M	41.8M
Current Deferred Revenue	14.0M	17.5M	16.3M	390K	448.5K	426.1K
Retained Earnings	57.0M	70.6M	88.1M	97.8M	115.4M	121.2M
Accounts Payable	2.6M	2.4M	2.3M	2.9M	3.7M	3.9M
Other Assets	1.3M	18.4M	2.1M	2.7M	3.1M	2.3M
Net Receivables	16.6M	19.6M	19.6M	22.0M	25.1M	13.3M
Good Will	23.8M	29.9M	41.7M	65.9M	65.9M	69.2M
Common Stock Total Equity	217K	221K	235K	237K	272.6K	194.7K
Short Term Investments	20.9M	214K	56.1M	63.6M	80.8M	84.8M
Inventory	39.5M	45.1M	46.1M	50.3M	52.3M	54.9M
Property Plant And Equipment Gross	30.1M	31.1M	17.1M	33.5M	61.3M	64.3M
Accumulated Other Comprehensive Income	(4.0M)	(1.5M)	(3.4M)	(6.0M)	(4.6M)	(4.4M)
Treasury Stock	(11.0M)	(11.6M)	(12.4M)	(13.0M)	(11.7M)	(11.2M)
Intangible Assets	23.2M	58.9M	52.7M	46.5M	41.7M	43.8M
Common Stock	217K	221K	235K	237K	239K	198.1K
Property Plant Equipment	14.9M	15.0M	32.1M	17.9M	20.6M	21.6M
Net Tangible Assets	108.2M	113.7M	135.5M	155.7M	179.1M	188.0M
Retained Earnings Total Equity	57.0M	70.6M	88.1M	97.8M	112.4M	118.1M
Capital Surpluse	105.9M	114.9M	181.6M	189.3M	217.7M	111.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for LeMaitre Stock Analysis

When running LeMaitre Vascular's price analysis, check to measure LeMaitre Vascular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LeMaitre Vascular is operating at the current time. Most of LeMaitre Vascular's value examination focuses on studying past and present price action to predict the probability of LeMaitre Vascular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LeMaitre Vascular's price. Additionally, you may evaluate how the addition of LeMaitre Vascular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC